Fosamax Cost in Illinois 2026: Alendronate Prices, Insurance, and Medicaid Coverage

What Does Fosamax Actually Cost in Illinois in 2026?

Generic alendronate is the price story here. At Illinois retail pharmacies in 2026, the average cash-pay price for a 30-day supply of generic alendronate 70 mg (four tablets, one per week) sits at roughly $15 per month. The Merck brand, Fosamax, carries a list price near $80 per month, though almost no patient pays that without insurance. The FDA first approved alendronate sodium in 1995 for postmenopausal osteoporosis, and the drug has been generic since 2008, which explains the dramatic price gap between brand and generic versions.

Retail prices vary by pharmacy. Large chains such as Walgreens, CVS, and Walmart Pharmacy in Chicago and Springfield have quoted prices between $12 and $22 for a four-tablet (28-day) supply of generic alendronate 70 mg as of January 2026. Independent pharmacies in suburban Cook County and downstate Illinois can price higher or lower depending on their wholesaler contracts. Calling ahead or using a pharmacy price-comparison tool before filling saves meaningful money.

The drug class itself, bisphosphonates, has broad off-patent penetration. According to prescribing data aggregated by the FDA Drug Database, alendronate is among the most-dispensed generic drugs in the United States. That volume keeps manufacturing competition high and prices low. For context, the FIT trial published in JAMA in 1998 enrolled 2,027 women with existing vertebral fractures and found alendronate reduced clinical fractures by approximately 47% versus placebo over three years, a finding that cemented alendronate's front-line status and drove the large prescribing volume that now keeps generics cheap [1].

Does Illinois Medicaid Cover Alendronate?

Illinois Medicaid (administered through Illinois Department of Healthcare and Family Services, HFS) covers alendronate with prior authorization (PA). The PA requirement is not automatic denial; it is a documentation step confirming the patient has a qualifying diagnosis such as postmenopausal osteoporosis, glucocorticoid-induced osteoporosis, or Paget disease of bone, all of which are FDA-labeled indications for alendronate [2].

Prescribers submit PA requests through the HFS Medical Electronic Data Interchange (MEDI) portal. Once approved, covered patients pay little to nothing at the pharmacy counter under the standard Illinois Medicaid pharmacy benefit. The Affordable Care Act requires state Medicaid programs to cover preventive services rated A or B by the US Preventive Services Task Force, and the USPSTF recommends screening for osteoporosis in women 65 and older [3]. That USPSTF mandate creates a policy environment in which Medicaid programs face pressure to cover osteoporosis treatment, not just screening.

Patients enrolled in Illinois Medicaid Managed Care Organizations (MCOs) such as Molina, Meridian, or Blue Cross Community Health Plan should verify the PA process with their specific MCO, because each MCO may apply slightly different criteria or timelines even within the statewide benefit framework. A prescriber's office can typically initiate the PA within one business day using the electronic prior authorization (ePA) tools integrated into common EHR systems.

Which Illinois Commercial Insurance Plans Cover Fosamax?

Most commercial plans sold in Illinois place generic alendronate on Tier 1 or Tier 2 of their drug formularies, which means patient cost-sharing of $0 to $30 per fill depending on plan design. Brand-name Fosamax typically lands on Tier 3 or Tier 4, meaning cost-sharing of $50 to $100 or more per fill. The Endocrine Society's 2019 clinical practice guideline on osteoporosis pharmacotherapy designates oral bisphosphonates as first-line agents, a guideline position that supports formulary placement at lower tiers [4].

ACA-compliant plans sold through the Illinois GetCovered marketplace must cover USPSTF A and B recommendations without cost-sharing. Because the USPSTF gives a B recommendation to osteoporosis screening for women 65 and older [3], many insurers extend zero-cost coverage to diagnostic testing. Treatment with alendronate after a confirmed diagnosis generally does require some cost-sharing, though Tier 1 generic placement keeps that share small.

Employer-sponsored plans in Illinois vary widely. A union health plan covering Chicago city workers may list generic alendronate at $0, while a high-deductible health plan (HDHP) tied to a health savings account may require the full ~$15 cash price until the deductible is met. Employees should check their Summary of Benefits and Coverage (SBC) document or call the pharmacy benefits manager (PBM) directly.

Medicare Part D, which covers Illinois residents aged 65 and older, also covers alendronate. Most Part D formularies list generic alendronate in Tier 1 or Tier 2. In 2026, the Medicare Part D out-of-pocket cap of $2,000 annually (enacted under the Inflation Reduction Act) limits total Part D spending [5]. Alendronate's low unit cost means most Part D patients hit no cap from this drug alone.

How to Use Discount Cards and Savings Programs in Illinois

GoodRx, RxSaver, and NeedyMeds are the three most widely used discount platforms for alendronate in Illinois. GoodRx prices in Illinois ZIP codes as of January 2026 range from $9 to $18 for a four-tablet (28-day) supply of generic alendronate 70 mg, depending on the chain and the specific coupon code generated. These discount cards cannot be combined with Medicare Part D or Medicaid, per CMS program rules [6].

Cash-pay patients under commercial insurance or with no insurance can present a GoodRx coupon directly at the pharmacy counter. The pharmacist runs the coupon instead of the insurance card, and the patient pays the discounted cash price. This works at most major Illinois retail pharmacies.

Merck's patient assistance program, Merck Helps, covers brand-name Fosamax for qualifying low-income patients who lack adequate insurance. Income thresholds and enrollment steps are managed through Merck's assistance portal. Given that generic alendronate costs $15 per month or less at most Illinois pharmacies, most prescribers steer uninsured patients toward the generic rather than the brand assistance program. The cost difference rarely justifies brand-specific paperwork.

The American College of Obstetricians and Gynecologists (ACOG) Practice Bulletin on Osteoporosis states: "For most postmenopausal women, oral bisphosphonates remain the treatment of choice given their efficacy, safety record, and low cost" [7]. That guideline endorsement, specifically calling out low cost, reinforces why generic alendronate is almost always the starting point for Illinois patients managing out-of-pocket expenses.

Is Compounded Alendronate Legal in Illinois?

Compounded alendronate is legal in Illinois when prepared by a state-licensed 503A compounding pharmacy operating under a valid patient-specific prescription. Section 503A of the federal Food, Drug, and Cosmetic Act governs traditional compounding pharmacies; Illinois additionally regulates these pharmacies through the Illinois Department of Financial and Professional Regulation (IDFPR) under the Illinois Pharmacy Practice Act (225 ILCS 85) [8].

Why would a patient need compounded alendronate? The standard commercial product is a 70 mg oral tablet. Patients with severe esophageal motility problems, documented tablet-swallowing difficulties, or specific intolerances to tablet excipients may receive a compounded oral solution or suspension. The FDA's guidance on compounding specifies that a compound may not be made to circumvent an FDA-approved product when the approved product is commercially available and not in shortage, so the prescriber must document a clinical rationale [9].

Cost of compounded alendronate from a 503A pharmacy varies. Some Illinois compounding pharmacies supply a monthly preparation at no charge when the patient's underlying insurance or compounding program covers it, while private-pay pricing ranges from $20 to $60 per month depending on formulation complexity. Generic commercial tablets at ~$15 per month are typically cheaper than compounded alternatives unless insurance covers the compound and not the tablet.

The following framework can guide Illinois prescribers deciding between generic commercial tablets and compounded alendronate:

1. Start with generic oral tablet 70 mg once weekly. Confirm no swallowing or GI contraindication.
2. If the patient reports esophageal intolerance or dysphagia, consider intravenous zoledronic acid (Reclast, 5 mg once yearly) as the preferred alternative, since IV administration bypasses GI issues entirely. Zoledronic acid 5 mg IV is covered by Medicare Part B (medical benefit, not Part D) for patients meeting bone density criteria [10].
3. Reserve compounded alendronate oral solution for patients who cannot tolerate tablets, cannot safely receive IV infusions, and have a licensed 503A pharmacy with documented experience compounding bisphosphonates.
4. Document the clinical rationale in the chart before sending a compound prescription.

Clinical Evidence Supporting Alendronate Use

Alendronate's evidence base is one of the most complete in osteoporosis pharmacology. The Fracture Intervention Trial (FIT), published in JAMA in 1998, remains the definitive reference [1]. In 2,027 postmenopausal women with low femoral neck bone density, alendronate 5 mg daily for two years then 10 mg daily for one year reduced clinical fractures by 47% versus placebo (risk ratio 0.53 to 95% CI 0.41 to 0.68, P<0.001) [1]. Hip fracture risk specifically fell by approximately 51% in patients who had pre-existing vertebral fractures at enrollment [1].

The FIT-2 arm, also published as part of the FIT program, extended findings to women without prevalent vertebral fractures, showing significant reductions in radiographic vertebral fractures over approximately 4.2 years [11]. A Cochrane systematic review of alendronate for primary and secondary prevention of osteoporotic fractures found consistent reductions in vertebral, non-vertebral, and hip fractures across trials [12].

Bone mineral density (BMD) increases with alendronate are durable. A study in the Journal of Bone and Mineral Research found lumbar spine BMD gains of 6.8% at three years and 7.5% at five years in patients on 10 mg daily [13]. The 70 mg once-weekly formulation, which is the standard commercial and generic tablet used today, demonstrated bioequivalence to the 10 mg daily tablet in a pharmacokinetic study [14].

Long-term use raises questions about atypical femoral fractures (AFF) and osteonecrosis of the jaw (ONJ). The American Society for Bone and Mineral Research task force report, referenced by the FDA's bisphosphonate safety communication, found AFF incidence of 3.2 to 50 per 100,000 person-years on bisphosphonate therapy, compared to background rates of 1.8 per 100,000 person-years [15]. That absolute risk is low but warrants a drug holiday discussion at five years of treatment. The National Osteoporosis Foundation (now Bone Health and Osteoporosis Foundation) guidelines suggest reassessing fracture risk every three to five years in stable patients [16].

Telehealth Prescribing of Alendronate in Illinois

Illinois permits telehealth prescribing of alendronate by licensed Illinois prescribers. Alendronate is not a controlled substance, so the federal Ryan Haight Online Pharmacy Consumer Protection Act does not impose the in-person visit requirement that applies to Schedule II through V drugs. A telehealth visit, conducted by video or telephone, is sufficient for an Illinois-licensed physician, advanced practice registered nurse (APRN), or physician assistant (PA) to issue a valid alendronate prescription [17].

Illinois enacted the Telehealth Act (215 ILCS 134) and related Department of Insurance regulations requiring commercial insurers to reimburse telehealth visits at parity with in-person visits for covered services. That means a patient's cost-sharing for the telehealth consultation that results in an alendronate prescription should mirror what they would owe for an office visit under their plan [18].

Practical steps for an Illinois patient pursuing alendronate via telehealth:

• Gather any recent DEXA scan results (a T-score of -2.5 or lower at the lumbar spine or femoral neck meets the WHO diagnostic threshold for osteoporosis) [19].
• Note fracture history. The FRAX calculator, endorsed by the World Health Organization, estimates 10-year fracture probability and is a standard tool in telehealth osteoporosis assessments [20].
• Have pharmacy information ready. The telehealth prescriber will send an electronic prescription (e-Rx) directly to an Illinois pharmacy of the patient's choice.
• After the prescription is sent, use a GoodRx code or Medicaid card at the pharmacy for lowest cost.

Monitoring Requirements After Starting Alendronate in Illinois

Starting alendronate is not a one-time action. Bone density monitoring and laboratory follow-up matter. The National Institutes of Health Office of Dietary Supplements notes that adequate calcium (1,000 to 1 to 200 mg per day in postmenopausal women) and vitamin D (600 to 800 IU per day) intake is essential to support bisphosphonate therapy [21]. Hypocalcemia can occur if calcium status is inadequate before starting alendronate; prescribers should check a serum calcium and 25-hydroxyvitamin D level at baseline.

DEXA scanning is recommended at baseline, then every one to two years during active treatment per Endocrine Society guidelines [4]. A repeat DEXA at two years that shows stable or increasing BMD is reassuring. A DEXA showing significant BMD loss despite alendronate adherence should prompt an evaluation for secondary causes of osteoporosis and possible switch to anabolic therapy such as teriparatide or romosozumab [4].

Renal function matters because alendronate is renally cleared and is contraindicated when estimated glomerular filtration rate (eGFR) falls below 35 mL/min/1.73m2 [2]. Illinois prescribers ordering alendronate for older patients should check a basic metabolic panel at baseline. Once alendronate is established and renal function is stable, annual chemistry checks are generally adequate.

Administration technique affects both efficacy and safety. Patients must take the tablet with at least 8 ounces (240 mL) of plain water, remain upright for at least 30 minutes, and take the dose at least 30 minutes before any food, beverage, or other medication. The FDA-approved prescribing information specifically warns that failure to follow these instructions raises the risk of esophageal adverse reactions including erosions and ulcers [2].

Comparing Alendronate to Other Osteoporosis Drugs on Cost in Illinois

Alendronate is the least expensive of the commonly prescribed osteoporosis drugs in Illinois in 2026. The table below compares approximate monthly cost for an Illinois cash-pay patient.

| Drug | Class | Typical Illinois Cash Price (2026) | Dosing Frequency | |---|---|---|---| | Generic alendronate 70 mg | Oral bisphosphonate | ~$15/month | Once weekly | | Risedronate (generic Actonel) 35 mg | Oral bisphosphonate | ~$25/month | Once weekly | | Zoledronic acid (generic Reclast) 5 mg | IV bisphosphonate | ~$200/infusion | Once yearly | | Denosumab (Prolia) | RANK-L inhibitor | ~$900/injection | Every 6 months | | Teriparatide (generic Forteo) | Anabolic PTH analog | ~$600/month | Daily injection | | Romosozumab (Evenity) | Sclerostin inhibitor | ~$1,800/month | Monthly injection x12 |

Zoledronic acid's annual cost (~$200) is comparable to alendronate's annual cost (~$180), but zoledronic acid requires an infusion center visit, which adds a facility fee. Under Medicare Part B, zoledronic acid is billed as a medical benefit when administered in a physician's office or outpatient infusion center, meaning 80% is covered by Medicare after the Part B deductible [10]. For patients who cannot adhere to weekly oral dosing, zoledronic acid once yearly can be a cost-effective alternative.

Denosumab and the anabolic agents (teriparatide, romosozumab) are reserved for patients at very high fracture risk, those who fail bisphosphonate therapy, or those who cannot tolerate bisphosphonates per Endocrine Society 2019 guidelines [4]. Illinois Medicaid requires PA for all these agents. Prior authorization criteria for teriparatide and romosozumab typically require documented bisphosphonate failure or intolerance plus a very high-risk DEXA result (T-score of -3.0 or lower, or -2.5 with fracture history) [22].

Who Qualifies for Alendronate in Illinois: FDA-Labeled Indications

Alendronate has five FDA-approved indications, each relevant to Illinois prescribers [2]:

1. Treatment of osteoporosis in postmenopausal women (70 mg once weekly)
2. Prevention of osteoporosis in postmenopausal women (35 mg once weekly)
3. Treatment of osteoporosis in men to increase bone mass (70 mg once weekly)
4. Treatment of glucocorticoid-induced osteoporosis in men and women (35 mg or 70 mg once weekly depending on sex and glucocorticoid dose)
5. Treatment of Paget disease of bone in men and women (40 mg once daily for six months)

The prevention indication (35 mg weekly, for postmenopausal women who are not yet osteoporotic but have low bone mass or osteopenia) is often overlooked. A woman with a T-score between -1.0 and -2.5 and a 10-year major osteoporotic fracture probability of 20% or greater (or hip fracture probability of 3% or greater) by FRAX meets National Osteoporosis Foundation thresholds for considering pharmacotherapy [16]. Illinois Medicaid's PA criteria align with these published thresholds.

Men with osteoporosis (T-score -2.5 or lower, or low-trauma fracture history) represent an underdiagnosed and undertreated population. A study published in JAMA Internal Medicine found that only 23% of men with hip fracture received osteoporosis treatment within one year of fracture [23]. Illinois prescribers can initiate alendronate 70 mg once weekly in qualifying men using the same telehealth pathway described above.